Portal de investigación
CONTRATOS JUAN RODES
Datos básicos
- Protocolo:
- 2016/197
- EUDRACT:
- NCT:
- Centro:
- Año de incio:
- 2017
- Año de finalización:
- 2020
Documentos
- No hay documentos
Participantes
Grupos y Plataformas de I+D+i
Financiadores - Promotores
Resultados del Ensayo Clínico
"Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction"
Papaccio, Federica; (...); Castillo, Josefa
Article. 10.1186/s13046-022-02591-z. 2023
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
Henriksen, Tenna Vesterman; (...); Andersen, Claus Lindbjerg
Article. 10.1158/1078-0432.CCR-21-2404. 2022
Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
Tarazona, Noelia; (...); Cervantes, Andres
Article. 10.1136/esmoopen-2020-000847. 2020
Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen.
Martinez-Ciarpaglini, Carolina; (...); Cervantes, Andres
Article. 10.1111/his.13900. 2019
In the literature: April 2020
Gambardella, V; (...); Cervantes, A
Editorial Material. 10.1136/esmoopen-2020-000749. 2020
In the literature: April 2022.
Ciardiello, D; (...); Cervantes, A
Editorial Material. 10.1016/j.esmoop.2022.100479. 2022
In the literature: August 2020.
Gambardella, Valentina; (...); Cervantes, Andres
Article. 10.1136/esmoopen-2020-000909. 2020
In the literature: December 2019
Gambardella, V; (...); Cervantes, A
Editorial Material. 10.1136/esmoopen-2019-000642. 2020
In the literature: February 2020
Roda, D; (...); Cervantes, A
Editorial Material. 10.1136/esmoopen-2020-000680. 2020
In the literature: June 2020.
Roda, Desamparados; (...); Cervantes, Andres
Article. 10.1136/esmoopen-2020-000832. 2020
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma.
Cabeza-Segura, M; (...); Fleitas, T
Article. 10.1038/s41416-022-02005-z. 2022
Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression
Martinez-Ciarpaglini, C; (...); Cervantes, A
Article. 10.1038/s41379-018-0124-5. 2019
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study.
Gambardella, Valentina; (...); Roda, Desamparados
Article. 10.1038/s41416-021-01502-x. 2021
New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing.
Tarazona, Noelia; (...); Cervantes, Andres
Editorial Material. 10.1016/j.annonc.2020.07.012. 2020
NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer.
Gambardella, V; (...); Cervantes, A
Article. 10.1158/1078-0432.CCR-18-2421. 2019
Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.
Gambardella, Valentina; (...); Cervantes, Andres
Article. 10.3390/jcm9093049. 2020
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.
Gambardella, V; (...); Fleitas, T
Article. 10.1016/j.ctrv.2020.102015. 2020
Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma.
Gambardella, V; (...); Cervantes, A
Review. 10.1093/annonc/mdz143. 2019
Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations.
Roda, D, Rosello, S, Cervantes, A
Editorial Material. 10.1093/annonc/mdz229. 2019
Will Organoids Fill the Gap towards Functional Precision Medicine?
Papaccio, Federica; (...); Cervantes, Andres
Article. 10.3390/jpm12111939. 2022
